ADARx chief scientist holds options on 513,401 shares

Q: What ADRX stock options are reported for its chief scientific officer?

The reported tranches cover 513,401 common shares at $3.2600 per share (expires February 25, 2033), 42,673 at $5.8400 (January 16, 2034), 42,673 at $7.0500 (February 11, 2035), and 68,276 at $6.3100 (January 27, 2036).

Each option award has a separate exercise price and expiration date, and vesting depends on continued service.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

ADARx Pharmaceuticals, Inc. reports that Chief Scientific Officer Alan Robert MacLeod holds four direct employee stock option tranches covering common shares: 513,401 at a $3.2600 exercise price, 42,673 at $5.8400, 42,673 at $7.0500, and 68,276 at $6.3100. Their expiration dates are February 25, 2033, January 16, 2034, February 11, 2035, and January 27, 2036, respectively. Each award vests in quarterly installments after an initial one-quarter vesting, subject to continued service.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider MacLeod Alan Robert

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
holding	Employee Stock Option (right to buy) ^F1	--	--	--
holding	Employee Stock Option (right to buy) ^F2	--	--	--
holding	Employee Stock Option (right to buy) ^F3	--	--	--
holding	Employee Stock Option (right to buy) ^F4	--	--	--

Holdings After Transaction: Employee Stock Option (right to buy) — 667,023 contracts (Direct)

Footnotes (4)

F1. Granted to the Reporting Person on February 26, 2023. 1/4 of the total number of shares vested and became exercisable on January 3, 2024 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F2. Granted to the Reporting Person on January 17, 2024. 1/4 of the total number of shares vested and became exercisable on January 1, 2025 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F3. Granted to the Reporting Person on February 12, 2025. 1/4 of the total number of shares vested and became exercisable on January 1, 2026 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F4. Granted to the Reporting Person on January 28, 2026. 1/4 of the total number of shares vest and become exercisable on January 1, 2027 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Key Figures

Option underlying common shares: 513,401 shares Option underlying common shares: 42,673 shares Option underlying common shares: 42,673 shares +1 more

4 metrics

Option underlying common shares 513,401 shares $3.2600 exercise price per share; expires February 25, 2033; granted February 26, 2023

Option underlying common shares 42,673 shares $5.8400 exercise price per share; expires January 16, 2034; granted January 17, 2024

Option underlying common shares 42,673 shares $7.0500 exercise price per share; expires February 11, 2035; granted February 12, 2025

Option underlying common shares 68,276 shares $6.3100 exercise price per share; expires January 27, 2036; granted January 28, 2026

Key Terms

Employee Stock Option (right to buy), exercisable, equal quarterly installments, continued service

4 terms

Employee Stock Option (right to buy) financial

"Employee Stock Option (right to buy)"

exercisable technical

"vested and became exercisable"

equal quarterly installments technical

"vest and become exercisable in equal quarterly installments"

continued service technical

"subject to the Reporting Person's continued service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ADRX stock options are reported for its chief scientific officer?

The reported tranches cover 513,401 common shares at $3.2600 per share (expires February 25, 2033), 42,673 at $5.8400 (January 16, 2034), 42,673 at $7.0500 (February 11, 2035), and 68,276 at $6.3100 (January 27, 2036).

When do ADRX Chief Scientific Officer Alan Robert MacLeod’s options vest?

One-quarter of the February 26, 2023 award vested January 3, 2024; one-quarter of the January 17, 2024 award vested January 1, 2025; and one-quarter of the February 12, 2025 award vested January 1, 2026. One-quarter of the January 28, 2026 award vests January 1, 2027. Remaining shares vest in equal quarterly installments over three years, subject to continued service on each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/26/2026 - 08:34 PM Accepted by SEC EDGAR 09/24/2026 - 06:37 PM

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

MacLeod Alan Robert

(Last)

(First)

(Middle)

C/O ADARX PHARMACEUTICALS, INC.

5871 OBERLIN DRIVE, SUITE 200

(Street)

SAN DIEGO

CALIFORNIA

92121

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
09/24/2026

3. Issuer Name and Ticker or Trading Symbol
ADARx Pharmaceuticals, Inc. [ ADRX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Scientific Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Employee Stock Option (right to buy)	⁽¹⁾	02/25/2033	Common Stock	513,401	$3.26	D
Employee Stock Option (right to buy)	⁽²⁾	01/16/2034	Common Stock	42,673	$5.84	D
Employee Stock Option (right to buy)	⁽³⁾	02/11/2035	Common Stock	42,673	$7.05	D
Employee Stock Option (right to buy)	⁽⁴⁾	01/27/2036	Common Stock	68,276	$6.31	D

Explanation of Responses:

1. Granted to the Reporting Person on February 26, 2023. 1/4 of the total number of shares vested and became exercisable on January 3, 2024 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.

2. Granted to the Reporting Person on January 17, 2024. 1/4 of the total number of shares vested and became exercisable on January 1, 2025 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.

3. Granted to the Reporting Person on February 12, 2025. 1/4 of the total number of shares vested and became exercisable on January 1, 2026 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.

4. Granted to the Reporting Person on January 28, 2026. 1/4 of the total number of shares vest and become exercisable on January 1, 2027 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Jiang Bian , Attorney-in-Fact	09/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR